NICE TAs

05/05/2020

TA417 : Nivolumab for previously treated advanced renal cell carcinoma

05/05/2020

TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer

04/05/2020

TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma

04/05/2020

TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer

04/05/2020

TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

04/05/2020

TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab

04/05/2020

TA442: Ixekizumab for treating moderate to severe plaque psoriasis

04/05/2020

TA479: Reslizumab for treating severe eosinophilic asthma

04/05/2020

TA413: Elbasvir–grazoprevir for treating chronic hepatitis C

04/05/2020

TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine

04/05/2020

TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea

04/05/2020

TA463: Cabozantinib for previously treated advanced renal cell carcinoma

04/05/2020

TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy

04/05/2020

TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

04/05/2020

TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma

01/05/2020

TA456: Ustekinumab for moderately to severely active Crohn's disease after previous treatment

01/05/2020

TA448: Etelcalcetide for treating secondary hyperparathyroidism

01/05/2020

TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma

01/05/2020

TA487: Venetoclax for treating chronic lymphocytic leukaemia

01/05/2020

TA443: Obeticholic acid for treating primary biliary cholangitis